HDAC6通过抑制Let-7i-5p引发TSP1/CD47介导的抗肿瘤发生与肝细胞癌吞噬作用
本研究探讨HDAC6在肝细胞癌中的抑癌机制,通过对HDAC6转染的Hep3B细胞进行miRNA差异表达分析,发现let-7i-5p靶向抑制TSP1。反义let-7i-5p、ppTSP1和rTSP1均抑制HCC细胞体外成瘤、血管生成和转移潜能,而CD47结合域特异性TSP1抗体可阻断这些效应;在自发性小鼠HCC模型中,HDAC6质粒、AS-let-7i-5p和rTSP1抑制肿瘤发生率和生长速率。
要点
- HDAC6通过抑制let-7i-5p去抑制TSP1表达,TSP1占据CD47受体阻断CD47-SIRPα介导的巨噬细胞抗吞噬作用。
- AS-let-7i-5p、ppTSP1和rTSP1对HCC细胞体外成瘤、血管生成和转移潜能的作用相似,TSP1中和抗体可减弱这些效应。
- CD47结合域特异性TSP1抗体成功阻断HDAC6质粒、AS-let-7i-5p、ppTSP1和rTSP1对HCC细胞体外血管生成和转移潜能的抑制作用。
核心结论
- HDAC6-let-7i-5p-TSP1调控通路通过与HCC细胞及肿瘤微环境邻近细胞表面的CD47受体相互作用,抑制HCC的肿瘤性和抗吞噬行为,为肝脏恶性肿瘤和转移的治疗提供了靶点。
研究设计与样本
- 对HDAC6转染的Hep3B细胞进行miRNA差异表达分析,结合公共转录组数据和miRNA靶点预测筛选候选miRNA,并行体外功能验证。
- 使用HCC细胞进行体外成瘤、血管生成和转移潜能实验,并采用自发性小鼠HCC模型评估肿瘤发生率和生长速率。
主要发现
- 体外功能验证显示let-7i-5p特异性抑制HCC中的TSP1。
- AS-let-7i-5p抑制HCC细胞体外成瘤;ppTSP1和rTSP1对同一HCC细胞表现出与AS-let-7i-5p相似的作用,而TSP1中和抗体处理显著减弱这些作用。
- HDAC6质粒、AS-let-7i-5p、ppTSP1和rTSP1处理均显著抑制HCC细胞体外血管生成和转移潜能,但CD47结合域特异性TSP1抗体共处理成功阻断这些作用。
- HDAC6恢复引起let-7i-5p抑制,从而去抑制TSP1表达,TSP1占据CD47受体阻断CD47-SIRPα介导的巨噬细胞抗吞噬作用。
- HCC来源的外泌体let-7i-5p抑制受体肝细胞细胞的TSP1;在自发性小鼠HCC模型中,HDAC6质粒、AS-let-7i-5p和rTSP1处理抑制肿瘤发生率和肿瘤生长速率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Histone deacetylase 6 (HDAC6) uniquely serves as a tumor suppressor in hepatocellular carcinogenesis, but the underlying mechanisms leading to tumor suppression are not fully understood. To identify comprehensive microRNAs (miRNAs) regulated by HDAC6 in hepatocellular carcinogenesis, differential miRNA expression analysis of HDAC6-transfected Hep3B cells was performed. Using integrative analyses of publicly available transcriptome data and miRNA target prediction, we selected five candidate miRNAs and, through in vitro functional validation, showed that let-7i-5p specifically suppressed thrombospondin-1 (TSP1) in hepatocellular carcinoma (HCC). Ectopic expression of antisense let-7i-5p (AS-let-7i-5p) inhibited in vitro tumorigenesis of HCC cells. In addition, treatments of partially purified TSP1 from culture cell media (ppTSP1) and recombinant TSP1 (rTSP1) exhibited similar effects with AS-let-7i-5p treatment on the same HCC cells, whereas TSP1 neutralizing antibody treatment significantly attenuated these effects. Notably, treatments of HDAC6 plasmid, AS-let-7i-5p, ppTSP1, and rTSP1 significantly suppressed in vitro angiogenesis and metastatic potential of HCC cells, but the co-treatment of TSP1 antibody specific to cluster of differentiation 47 (CD47) binding domain successfully blocked these effects in the same cells. Furthermore, we demonstrated that recovery of HDAC6 elicited let-7i-5p suppression to de-repress TSP1 expression; therefore, it occupied the CD47 receptor to block CD47-SIRPα-mediated anti-phagocytosis of macrophage in HCC. We also observed that HCC-derived exosomal let-7i-5p suppressed TSP1 of recipient hepatocyte cells. Treatments of HDAC6 plasmid, AS-let-7i-5p, and rTSP1 suppressed tumor incidence as well as tumor growth rates in a spontaneous mouse HCC model. Conclusion: Our findings suggest that the HDAC6-let-7i-5p-TSP1 regulatory pathway suppresses neoplastic and antiphagocytic behaviors of HCC by interacting with cell surface receptor CD47 in HCC and neighboring cells of tumor microenvironment, providing a therapeutic target for the treatment of liver malignancy and metastasis.
引用
- Yang HD, Kim HS, Kim SY, et al. HDAC6 Suppresses Let-7i-5p to Elicit TSP1/CD47-Mediated Anti-Tumorigenesis and Phagocytosis of Hepatocellular Carcinoma. Hepatology. 2019. PMID: 30991448. doi:10.1002/hep.30657
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。